ImmuneSensor Therapeutics Gains Approval from Australian Authorities to Begin First-in-Human Phase 1 Trial for cGAS Inhibitor Drug IMSB301.

GlycoNex has declared the successful conclusion of a Phase 1 clinical trial for its denosumab biosimilar, SPD8.

Antibody-Drug Conjugates (ADCs), as a part of precision medicine, target tumor cells by combining the specificity of antibodies with the potent effects of cytotoxins.

The European Medicines Agency has accepted Bristol Myers Squibb's application for CAR T cell therapy Breyanzi for treating relapsed or refractory follicular lymphoma.

Aug 21st latest updates in the global new drug development field, including progress in new drug research and development, transaction information, and partnership developments.

This trial aims to evaluate the safety and tolerability of MOMA-313, an innovative and highly potent, selective oral inhibitor targeting polymerase theta helicase.

The proposal seeks regulatory approval under the TGA’s Clinical Trial Notification (CTN) scheme to initiate a first-in-human Phase 1 clinical trial for SAT-3247.

This trial is evaluating MRT-6160, an MGD aimed at VAV1, intended for treating systemic and neurological autoimmune conditions.

The EMA has accepted a Type II Variation Application for ENHERTU® to treat patients with HER2 low or ultralow metastatic breast cancer after at least one endocrine therapy.

uniQure N.V. has reported that the inaugural patient has received a dose in a Phase I/IIa clinical trial of AMT-191 targeting Fabry disease.

NewBridge will have exclusive distribution rights in Algeria, Iraq, Libya, and Jordan for CRYSVITA® (burosumab) for the treatment of X-linked hypophosphatemia (XLH) and tumor-induced osteomalacia (TIO).

Imfinzi received Priority Review and Breakthrough Therapy Designation in the US for patients with limited-stage small cell lung cancer.